Proteomic Assessment of iTRAQ-Based NaoMaiTong in the Treatment of Ischemic Stroke in Rats

<table class="fixed-width table-group" id="tab3"><tr><td><table class="table"><colgroup><col style="width:9.08em"/><col style="width:6.85em"/><col style="width:6.85em"/><col style="width:7.96em"/></colgroup><tr><td class="thead-hr" colspan="4"><hr/></td></tr><tr class="thead"><td class="align_left">Group</td><td class="align_center">Up-protein</td><td class="align_center">Down-protein</td><td class="align_center">Total differential protein</td></tr><tr><td class="thead-hr" colspan="4"><hr/></td></tr><tr><td class="align_left">MCAO VS NMT</td><td class="align_center">252</td><td class="align_center">34</td><td class="align_center">286</td></tr><tr><td class="align_left">MCAO VS sham operation group</td><td class="align_center">122</td><td class="align_center">40</td><td class="align_center">162</td></tr><tr class="table-tr"><td colspan="4"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

<div>Screening results of DEPs (1.2-fold differential protein).</div>

Evidence-Based Complementary and Alternative Medicine

tab3

Table 3

Table 3: Proteomic Assessment of iTRAQ-Based NaoMaiTong in the Treatment of Ischemic Stroke in Rats 